Receptor Pharmacology
Section snippets
Summary
Despite clear evidence for a distinct amylin pharmacology and localization of such pharmacology to sites such as the nucleus accumbens, efforts to clone an amylin receptor were fruitless for over a decade. This enigma led many to doubt the status of amylin as a bona fide hormone. Yet it became apparent during those cloning efforts that, whatever the amylin receptor was, it was somehow similar to a calcitonin receptor.
The enigma of the amylin receptor was solved following the identification of
Molecular and Biochemical Characterization
The path leading to the molecular identity of the amylin receptor was circuitous. Before its characterization, several studies had suggested a close relationship between the amylin receptor and products of the calcitonin receptor gene. High‐affinity amylin binding sites were reported in MCF‐7 human breast carcinoma cells (Chen 1997, Zimmermann 1997). Expression cloning experiments using a peptide antagonist of amylin and calcitonin receptors identified two isoforms of the calcitonin receptor
Brain Distribution
The distribution of sites corresponding to amylin receptors was first identified by Sexton et al. in 1988 (Sexton et al., 1988). They were first termed C3 binding sites, characterized as calcitonin binding sites that also had high affinity to both sCT and CGRP (Sexton et al., 1988). But, since amylin had just been discovered, these authors did not recognize that the C3 sites also bound amylin with high affinity. The discovery that these sites contained amylin receptors was made by Beaumont in
Definition of Amylinomimetic Class
Before molecular characterization of amylin receptors, pharmacological and anatomic characterization of an amylin receptor class was apparent, with selective ligands showing distinctive patterns of activities in bioassays, affinities in binding studies, and distributions of selective binding. These distinctions allowed for a definition of an amylinomimetic class of ligands.
Binding potencies at membranes from the nucleus accumbens in rat (Beaumont et al., 1993) indicated a unique pharmacology
References (62)
- et al.
Molecular cloning of 2 receptors from rat brain with high affinity for salmon‐calcitonin
FEBS Lett.
(1993) - et al.
Peripheral amylin activates circumventricular organs expressing calcitonin receptor a/b subtypes and receptor‐activity modifying proteins in the rat
Brain Res.
(2004) - et al.
Novel receptor partners and function of receptor activity‐modifying proteins
J. Biol. Chem.
(2003) - et al.
Amylin or CGRP (8–37) fragments reverse amylin‐induced inhibition of 14C‐glycogen accumulation
Biochem. Biophys. Res. Commun.
(1991) - et al.
Novel calcitonin‐(8–32)‐sensitive adrenomedullin receptors derived from co‐expression of calcitonin receptor with receptor activity‐modifying proteins
Biochem. Biophys. Res. Commun.
(2003) - et al.
Evidence for a new subclass of calcitonin/calcitonin gene‐related peptide binding site in rat brain
Neurochem. Int.
(1988) - et al.
In vitro autoradiographic localization of amylin binding sites in rat brain
Neuroscience
(1994) - et al.
Comparison of the in vitro and in vivo pharmacology of adrenomedullin, calcitonin gene‐related peptide and amylin in rats
Eur. J. Pharmacol.
(1996) - et al.
8–37h‐CGRP antagonizes actions of amylin on carbohydrate metabolism in vitro and in vivo
FEBS Lett.
(1991) - et al.
8–37hCGRP, an amylin receptor antagonist, enhances the insulin response and perturbs the glucose response to infused arginine in anesthetized rats
Mol. Cell Endocrinol.
(1992)
Selective amylin antagonist suppresses rise in plasma lactate after intravenous glucose in the rat—Evidence for a metabolic role of endogenous amylin
FEBS Lett.
Multiple ramp domains are required for generation of amylin receptor phenotype from the calcitonin receptor gene product
Biochem. Biophys. Res. Commun.
Differential calcitonin gene‐related peptide (CGRP) and amylin binding sites in nucleus accumbens and lung: Potential models for studying CGRP/amylin receptor subtypes
J. Neurochem.
Amylin inhibits bone resorption by a direct effect on the motility of rat osteoclasts
Exp. Physiol.
Further studies on the mode of action of calcitonin on isolated rat osteoclasts—pharmacological evidence for a 2nd site mediating intracellular Ca2+ mobilization and cell retraction
J. Endocrinol.
Molecular cloning and functional expression of a third isoform of the human calcitonin receptor and partial characterization of the calcitonin receptor gene
Endocrinology
Receptor-based screening methods for amylin agonists and antagonists
U.S. Patent
Receptor-based screening methods for amylin agonists and antagonists
European Patent EP0529065
High affinity amylin binding sites in rat brain
Mol. Pharmacol.
Differential antagonism of amylin's metabolic and vascular actions with amylin receptor antagonists
Can. J. Physiol. Pharmacol.
Coupling of two cloned rat calcitonin receptor isoforms to adenylyl cyclase and phospholipase C
Regulation of muscle glycogen metabolism by CGRP and amylin: CGRP receptors not involved
Br. J. Pharmacol.
The demonstration of vasodilator activity of pancreatic amylin amide in the rabbit
Am. J. Pathol.
Renal amylin binding in normotensive and hypertensive rats: Effects of angiotensin converting enzyme inhibition with perindopril
J. Hypertension
Expression cloning and receptor pharmacology of human calcitonin receptors from MCF‐7 cells and their relationship to amylin receptors
Mol. Pharmacol.
Calcitonin gene‐related peptide receptor antagonist human CGRP‐(8–37)
Am. J. Physiol.
Vasodilator responses to calcitonin gene‐related peptide (CGRP) and amylin in the rat isolated perfused kidney are mediated via CGRP (1) receptors
J. Pharmacol. Exp. Ther.
Comparative distribution of receptors for amylin and the related peptides calcitonin gene related peptide and calcitonin in rat and monkey brain
Can. J. Physiol. Pharmacol.
Multiple amylin receptors arise from receptor activity‐modifying protein interaction with the calcitonin receptor gene product
Mol. Pharmacol.
Identifying cpds. which affect amylin activity—using an in‐vivo biological model in which amylin increases levels of lactate and glucose
World Patent Application
Expression of the human calcitonin/CGRP gene in lung and thyroid
EMBO J.
Cited by (33)
Amylin and its G-protein-coupled receptor: A probable pathological process and drug target for Alzheimer's disease
2017, NeuroscienceCitation Excerpt :Our in vitro study showed that human amylin with a concentration from 10 ng/ml (∼2.5 nM) to 10 μg/ml (∼2.5 μM) was beneficial to antagonize the neurotoxicity caused by aggregated Aβ1-42 in rat cortical neurons. The average fasting plasma amylin concentrations are in the range of 4–25 pmol/l in healthy humans (Nyholm et al., 1998), the peak of amylin in the amylin treatment we conducted for the mice was ∼1 nmol/l and the half-life of exogenous amylin or pramlintide is about 20–45 min in vivo (Colburn et al., 1996; Young, 2005b). Since MCI and AD patients have lower concentrations of plasma amylin than healthy controls (Adler et al., 2014; Zhu et al., 2015), the potential benefits of amylin-type peptides with a physiological concentration as a neuropeptide should not be ignored.
Islet amyloid polypeptide: Another key molecule in Alzheimer's pathogenesis?
2017, Progress in NeurobiologyCitation Excerpt :IAPP receptor is important for mediating the physiological roles of IAPP. It is a heterodimer complex of the calcitonin receptor (CTR) and a receptor activity modifying protein (RAMP) (McLatchie et al., 1998; Muff et al., 1999; Young, 2005). CTR is a seven transmembrane domain G protein-coupled receptor while the RAMP is a non-receptor protein with three currently known isoforms named RAMP1-3.
Effects of intrathecal amylin on formalin-induced nociception and on cAMP accumulation in the rat embryonic spinal cells
2016, NeuropeptidesCitation Excerpt :Hence, we used AMY receptor antagonists rAMY8-37, AC187 and CGRP8-37 to characterize the nature of receptors that mediate inhibitory effects of AMY on the formalin-induced hyperalgesia. AC187 is generally accepted as a good discriminator of amylinergic responses (Young, 2005). rAMY8-37 is also generally accepted as a selective but weak antagonist at AMY receptors with an affinity profile of AMY1 > AMY3 ⋙ rCT (Hay et al., 2005).
Amylin activates distributed CNS nuclei to control energy balance
2014, Physiology and BehaviorCitation Excerpt :The CTR can be activated by several closely related peptides including calcitonin, amylin, adrenomedullin, and CGRP. The CTR alone has the highest affinity for calcitonin [25,26], but enhanced selectivity for amylin binding is conferred by association with a RAMP [27,28], of which there are three possible subtypes for the amylin receptor complex (RAMP1, RAMP2, RAMP3) [29]. Together with the two splice variants of CTR, this totals six unique CTR/RAMP combinations that can form a functional amylin receptor [30], although RAMP1 and RAMP3 may confer greater amylin binding selectivity than RAMP2 [27,28].
Cardiovascular Neuroendocrinology
2012, Handbook of NeuroendocrinologyActions of β-amyloid protein on human neurons are expressed through the amylin receptor
2011, American Journal of Pathology